Pharmaceutical scientists involved with APS

Who We Are

The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.

Pharmaceutical Scientists are experts in the research, development and manufacture of medicines. They have a major role in the regulation of medicines and understanding their use in patients.

What We Do

The APS is a not-for-profit organisation. We use revenues to champion innovation and opportunity in Pharmaceutical Sciences thereby improving the development and delivery of medicines for the benefit of patients. Our four key strategic themes, which are the foundation of all APS activities, are:

  • Establish and promote the reputation of Pharmaceutical Sciences and Scientists
  • Influence policy
  • Further scientific knowledge
  • Promote cateers

Board Roles & Responsibilities

Each member on the board and advisory board is
responsible for a specific area of development

Accreditation- Bill Dawson

Education- John Wahlich

Events- Carol O’Connor

Finance – Geoff Davison

Focus Groups- Michael Leane

PharmSci 2018- John Wahlich

Pharm Sci 2019- Fran Greco

Sponsorship- Linda Hakes, Trefor Jones

Student & Academic liaison- Jayne Lawrence, Yvonne Perrie

Marketing- Carol O’Connor

Membership – Geoff Davison

Social Media – Helen Barker

Strategy – Mark McAllister, Helen Barker, Julie Cahill

Website – Carol O’Connor, John Wahlich

The APS Board

The APS Board

Dr Mark McAllister
Dr Mark McAllisterChair
Dr Mark McAllister is a Senior Scientific Director in the Drug Product Design group at Pfizer (Sandwich) with responsibility for mid-to-late stage development projects. He is a Pharmacy graduate from Queen’s University Belfast and has a pharmaceutics PhD from Aston University. Mark has over 20 years industrial development experience and has specialised in oral delivery systems and biopharmaceutics. He is the current chairman of the Academy of Pharmaceutical Sciences, APS biopharmaceutics focus group leader and a fellow of the Royal Pharmaceutical Society. Mark co-leads the IMI ‘OrBiTo’ project, an academic/industrial collaboration, developing the next generation of models to predict oral absorption.
Helen L Barker
Helen L BarkerPharmaceutical Scientist
Pharmaceutical Scientist and Business Leader
Board member of the Academy of Pharmaceutical Science, elected in 2008, Faculty Fellow of the Royal Pharmaceutical Society, a Chartered Chemist and Chartered Scientist.
Head of Pharmaceutical Development at Reneo Pharma, with a strong background in large pharma and biotech companies.
As managing director of Project-ion Ltd, supports a number of biotech and non-profit organizations, including the role of COO at Calcico Therapeutics.
Enjoyed a range of positions in Pfizer, Bristol-Myers Squibb, multiple start-up companies and academia, enabled by degrees in Chemical and Pharmaceutical Science and an MBA.
Professor Yvonne Perrie
Professor Yvonne Perrie Chair of Drug Delivery
Yvonne is the Chair in Drug Delivery within Strathclyde Institute for Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, Scotland. Prior to this appointment, she was Professor in Drug Delivery, within Aston University, Birmingham, England (2007-2016). Yvonne has a BSc (First-Class Hons) in Pharmacy from Strathclyde University and she attained her PhD from the University of London under the supervision of Prof Gregoriadis. Yvonne’s research is multi-disciplinary and is focused on the development of drug carrier systems to facilitate the delivery of drugs and vaccines, providing practical solutions for current healthcare problems. Yvonne has published approximately 100 peer-reviewed papers, 5 patents and 4 text books. She is a Fellow of the Society of Biology, a Fellow of the Royal Pharmaceutical Society, a member of the College of Fellows for the Controlled Release Society and an Eminent Fellow of the Academy of Pharmaceutical Sciences. Externally Yvonne is Editor in Chief of Pharmaceutics and the Journal of Liposome Research and Associate Editor for the Journal of Drug Targeting and the Journal of Pharmacy and Pharmacology.
Professor Jayne Lawrence
Professor Jayne LawrenceVice Chair
Jayne is Vice-Chair of APS. She is currently Head of the Division of Pharmacy and Optometry, Manchester University. Prior to this Jayne was Professor and Head of the Pharmaceutical Biophysics Group, Institute of Pharmaceutical Science, King’s College London and Chief Scientist at the Royal Pharmaceutical Society. Jayne is a pharmacist who, in addition to working in academia, has spent time working in community and hospital pharmacy and the industrial pharmacy. Her research is focused on improving the delivery of drugs and genetic material, with special interest in increasing drug solubility.
Dr Hannah Batchelor
Dr Hannah BatchelorSenior Lecturer
Dr Hannah Batchelor Is a senior Lecturer in Pharmaceutics, Formulation and Drug Delivery at the University of Birmingham.
Hannah is a pharmaceutical scientist who has worked in academia, the NHS and within pharmaceutical industry. Her research interests lie in the optimisation of drug formulations to maximise their biopharmaceutical performance and acceptability to children. Her research is informed by the views of children, young people and parents to ensure that the patients are at the centre of new developments.
She has been invited to present at many National and International scientific meetings as well as a TED talk.
Dr Michael Leane
Dr Michael LeanePrincipal Scientist
Michael Leane is a Principal Scientist with Bristol-Myers Squibb. He graduated with a Pharmacy degree from Trinity College Dublin and has a PhD in Advanced Drug Delivery from the University of Nottingham. He has previously worked at Elan Pharmaceutical Technologies focusing primarily on the development of new solid dosage form delivery systems for poorly permeable drugs and at Phaeton Research investigating novel gastroretentive platforms. He joined Bristol-Myers Squibb in 2005, with an initial role as formulation scientist leading a team concentrating on development of a poorly-soluble compound. His current role at BMS is within drug product development where he specialises in the optimisation of API particle properties to facilitate drug product manufacture.
He is a committee member and former chair of the APS Materials Science Focus Group and has authored and co-authored a number of publications around amorphous formulation development and novel characterisation techniques. He is co-lead of an APS-sponsored working group aiming to establish a Manufacturing Classification System for oral solid dosage forms. This initiative developed from an APS conference in 2013 and has grown through the publication of a peer-reviewed position paper and interaction with other international pharmaceutical science bodies such as the AAPS and APV.
Dr Geoff Davison
Dr Geoff DavisonTreasurer
Geoff is CEO of Bionow the membership organisation for life science businesses in the North of England. Prior to this Geoff was founder and Technical Director of Biorite Ltd and Advanced Biomedical Ltd both spin-out companies from the University of Manchester. Geoff has a degree in Biochemistry and a PhD from the School of Pharmacy, University of Manchester where he began his career undertaking postdoctoral research.
Dr Fran Greco
Dr Fran GrecoAssociate Professor
Francesca Greco is an Associate Professor in Drug Delivery at the Reading School of Pharmacy and sits on the board of directors of the Academy of Pharmaceutical Sciences. She graduated from Pisa University with an MPharm (110/110 cum laude), which included a one-year research project at Pharmacia (now part of Pfizer) in Nerviano, Milan (Italy). She then undertook a PhD in drug delivery under the supervision of Prof. Ruth Duncan and Prof. Rob Nicholson, in Pharmacy, Cardiff University (awarded in March 2006). Immediately after completion of her PhD, Francesca was appointed to a lectureship at the Reading School of Pharmacy (July 2006) and she was then promoted to Associate Professor in May 2012. Her research in polymer-drug conjugates led to several publications in peer-reviewed journals and her work has been presented at national and international conferences. Francesca was awarded prizes for her research, including an invitation to the “Roche Symposium for leading scientists of the next decade” (Basel, Switzerland, 2007). Francesca acts as referee for scientific journals including the Journal of Controlled Release, Molecular Pharmaceutics and the Journal of Biomaterials Applications and for funding bodies, including EPSRC. Francesca leads an interdisciplinary research group currently constituted by 4 PhD students.
Dr Julie Cahill
Dr Julie CahillProduct Development
Julie is Director, Product Development at AstraZeneca R&D.
Bob Clay
Bob Clay

The Advisory Board

The Advisory Board

Jo Craig
Jo Craig
Jo is a Pharmacist and has spent her entire career working in the pharmaceutical industry with a focus on pharmaceutical development, product quality and the introduction of new manufacturing technologies. She is currently Senior Vice President CMC (Chemistry Manufacturing & Controls) for two clinical stage biotech companies, NeRRe and KaNDy Therapeutics, located at the Stevenage Biosciences Catalyst, a role she has held since Summer 2018. Previously, Jo spent over 30 years at GlaxoSmithKline where her career spanned many leadership roles in CMC product development, most recently as Vice President of Technology & Strategy, Product Development & Supply. Jo continues to be involved with the Medicines Manufacturing Industry Partnership (MMIP) where she has been influential in aligning Pharma and UK Government on future areas for investment. Jo is an Eminent Fellow of the Academy of Pharmaceutical Sciences, UK and has been an Advisor to the APS Board for several years.
Dr Linda Hakes
Dr Linda Hakes
Linda has more than 40 years’ experience in the pharmaceutical industry, having worked for companies such as Glaxo, Marion Merrell Dow, Celltech, Eli Lilly, Schwarz Pharma AG and UCB Biosciences. Her experience covers pharmaceutical development, preclinical development, clinical trial supplies, quality assurance and project leadership. Since 2016 Linda has been an independent consultant with a focus on pharmaceutical development and development strategy.
Linda is a Vice President of FIP (International Pharmaceutical Federation), a member of the Assembly of Royal Pharmaceutical Society (RPS) and the immediate past Chairman of the Academy of Pharmaceutical Sciences. She is also visiting Professor at Sunderland University and is eligible to be a Qualified Person. Linda is a Fellow of both the Royal Pharmaceutical Society and FIP.
Professor Trevor Jones
Professor Trevor Jones
Trevor is Chairman of the CRO Simbec-Orion; Board member of the investment company Arix Bioscience; and the Oxford based Drug Discovery Company, e-Therapeutics. He was a Director of Allergan Inc. (USA), R&D Director of The Wellcome Foundation and Director General of The ABPI.
He holds honorary degrees and Gold Medals from 7 universities; is a founder member of Medicines for Malaria Venture (MMV); member of The UK Government Regulatory Agency, The Medicines Commission; advisor to the Cabinet Office on the Human Genome project; Chair of the UK Government Advisory Group on Genetics Research; member of the Wales Government Bevan Commission on health; advised the Government of the Netherlands TiPharma on Life Science and is a member of the EU Commission IMI Scientific Advisory Board.
Professor Bill Dawson
Professor Bill Dawson
Bill Dawson is a previous Chair of APS and is now an Advisory Board member with responsibility for the accreditation process. His career was primarily in industry, mostly as Research Director for Eli Lilly and Co in the UK but has been an academic and a community pharmacist. Currently he runs a health care consultancy advising universities and SMEs on development and commercialisation of new medicines and devices. He is a visiting professor at the universities of Durham and Nottingham and is an external adviser to Stevenage Bioscience Catalyst, an open innovation campus.
Mrs Christine Glover
Mrs Christine Glover
Christine has been involved with APS since its inception , she is always anxious to promote the broad spectrum of pharmaceutical science to the wider world. As a past president of the Royal Pharmaceutical Society she brings a breadth of political and communications experience to the board .
Christine works as a health consultant with the emphasis on an holistic approach to health and wellbeing .
Professor David Jones
Professor David Jones
Currently I am Pro-Vice-Chancellor (Education and Students) and Professor of Biomaterials Science at Queen’s University Belfast. As an internationally renowned pharmaceutical/biomedical engineer my research seeks to provide engineering solutions to medical and pharmaceutical problems. These include innovations in the design of drug containing implants and medical devices to that reduce the morbidity and mortality associated with medical device related infection. Commercialisation of this research has occurred and is ongoing. Within the pharmaceutical domain, I have developed novel implants for the treatment of local diseases and, additionally, engineering technologies to develop new dosage forms, including strategies in which drugs of low solubility (negating their clinical utility) may be developed for clinical usage.
Dr Gary Parsons
Dr Gary Parsons
Dr Tommy Dolan
Dr Tommy Dolan
Tommy completed his undergraduate and postgraduate education in Pharmacy at the University of Strathclyde. Following that he undertook post doctoral study at the universities of Strathclyde and Glasgow assessing novel drug carrier systems as immunological adjuvants. He first joined Controlled Therapeutics in 1988 where he was involved in researching the use of hydrogels as novel drug delivery systems for a range of indications. In 1990 Tommy commenced his career at Pfizer Global Research and Development at Sandwich joining as a formulation scientist. Since joining Pfizer he has held a variety of positions in Pharmaceutical Research and Development in that time ultimately heading the department since 2002. Tommy has been involved in the development of a number of drug development programs and wide variety dosage form types in that time many of which are now marketed products.
Professor Mike Hannay
Professor Mike Hannay
Mike is Managing Director of the East Midlands Academic Health Science Network (AHSN), an NHS organisation charged with transforming the health of 4.6 million people living in the East Midlands and stimulating wealth creation in the region. Mike joined the NHS after 28 years developing new medicines. Mike has managed and contributed to the development of the formulations, devices, drug substance manufacturing processes and associated test methods for a number of innovative new medicines.
As a member of the Advisory Board Mike supports the board in developing strategies that promote the pharmaceutical sciences and encourage high standards of practice.
Dr Carol O'Connor
Dr Carol O'ConnorScientific Administrator
Carol has over 20 years drug development, managerial and project management experience working in the biotechnology, pharmaceutical and device industries. She is a registered Pharmacist with a PhD from the University of Manchester, in controlled drug release. Her background is in pharmaceutical development and CMC regulatory affairs with scientific and technical knowledge in drug delivery combined with business and commercial skills. This she has gained from a career working for initially Fisons and then Astra Zeneca in Pharmaceutical development and project management. Moving into Programme Management with Quadrant Healthcare working with novel particle technologies and biologicals, with a range of partnering companies. She is currently a consultant, involved in a range of projects at all stages of drug development, for in house development and partnering from small start-up companies to multinational companies.